Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Color-Coded Microspheres Make Vessel Embolization Easier

By HospiMedica International staff writers
Posted on 13 Jan 2009
Syringes that are pre-filled with a range of color-coded embolization microspheres enable physicians to accurately perform blood vessel occlusions.

The Embozene Color-Advanced microspheres are intended for treatment of hyper-vascularized tumors such as uterine fibroids, ArterioVenous Malformations (AVMs), hepatocellular carcinomas (HCCs), and other highly vascularized cancers. More...
The microspheres consist of a hydrogel core and an exterior shell made from Polyzene-F (poly[bis(trifluroexthoxy)phosphazene]), and are color- enhanced with a different color for each size for increased procedural safety, efficiency, and visibility. The microspheres are available in 40 micrometers, 100 micrometers, 250 micrometers, 400 micrometers, 500 micrometers, 700 micrometers, and 900 micrometers sizes, in both 1 ml and 2 ml pre-filled syringes and vials. The microspheres are precisely calibrated and retain their shape after passing through a catheter, allowing them to stay in the delivery suspension for an extended period.

The color-coding improves particle visibility, increases procedural safety, and optimizes handling and convenience for the physician. Instant visual confirmation of the microsphere size eliminates potential waste due to size uncertainty, when operating with multiple microsphere sizes. Using different containers prevents contamination of saline and contrast syringes during the procedure. The increased visibility allows confirmation of microsphere levels in the suspension prior to and during injection, and reduces the risk of injecting too many or very few particles because the microspheres are visible, especially when using smaller sizes. The Embozene Color-Advanced microspheres are a product of CeloNova BioSciences (Newnan, GA, USA), and have been approved by both the U.S. Food and Drug Administration (FDA) and the European Community (CE Marking).

"From the outset, we took a different approach to developing our Embozene Microspheres by asking physicians and medical scientists for the qualities and characteristics that the ideal embolic device should have,” said Thomas A. Gordy, President and CEO of CeloNova BioSciences. "Then we engineered Embozene Microspheres to have those properties, which are made even better with Polyzene-F, our proprietary polymer.”

Related Links:
CeloNova BioSciences




Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Fetal Monitor
BT-380
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The device is worn on a finger and measures blood pressure without an arm‑compressing cuff (Photo courtesy of Sky Labs)

Ring-Type Cuffless Monitor Becomes First Added to Official Hypertension Guidelines

Detecting nocturnal and morning hypertension often requires out-of-office assessment, but conventional cuff-type monitors can disrupt sleep. New national guidance in South Korea expands 24-hour monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.